Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial

Authors:

Abstract
No abstract available
Funding Information
  • National Key Research and Development Program of China (2021YFC2400600 / 2021YFC2400601)
  • National Natural Science Foundation of China (82102776)
  • National Natural Science Foundation of China (82072958)
  • National Natural Science Foundation of China (82272699)

This publication has 49 references indexed in Scilit: